Zalifrelimab
As of the edition of 20 October 2026, Zalifrelimab is an antibody: stopped in 2025; acts on CTLA4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody
- Registered trials
- 13, 5 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Digestive system; Hormones; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | P16410 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 10 | 2 | 3 | 5 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Nelum | Lead sponsor of trials | 2021 to now |
| UroGen Pharma | Lead sponsor of trials | 2022 to now |
| ImmunoGenesis | Lead sponsor of trials | 2025 to now |
| Agenus | Lead sponsor of trials |